ClinicalTrials.gg
CompletedNCT02576964Updated Nov 2, 2016

A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer

A Phase 2 interventional study of Capecitabine and Peginterferon alfa-2a in Carcinoma, Hepatocellular, sponsored by Hoffmann-La Roche. Completed at 8 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing capecitabine in Carcinoma, Hepatocellular — 2 open to participants now, 2 under way, 1 of them phase 3. Capecitabine · Carcinoma, Hepatocellular.

Enrollment
19th of 22
16 · median 40
Started
2005
the only one that year
Phase 2
13 of 24
none open now
Registered
19th of 24
by date
Lead sponsor
1 of 24
Hoffmann-La Roche

Among the 24 studies testing capecitabine in Carcinoma, Hepatocellular, this one is the 19th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2005, is one of 13 in phase 2, and was the 19th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

2 of the 24 studies testing capecitabine in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing capecitabine in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of capecitabine (Xeloda) in combination with peginterferon alfa-2a (Pegasys) in participants with advanced liver cancer who have had no prior treatment. The anticipated time on study treatment is until disease progression, and the target sample size is 43 individuals.

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 to 75 years of age
  • Locally advanced or liver cancer with and not eligible for any standard therapy

Exclusion criteria

Exclusion Criteria:

  • Previous treatment for liver cancer
  • Main portal vein involvement
  • Bone, brain, or
  • cardiac disease
  • Malabsorption syndrome or lack of physical integrity of the upper gastrointestinal tract
  • History of other cancer, except basal cell skin cancer or in situ cancer of the cervix
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Capecitabine + Peginterferon alfa-2a

    Treatment-naive participants with advanced liver cancer will receive combination treatment with capecitabine (1000 milligrams per meter-squared \[mg/m\^2\] twice daily orally on Days 1 to 14 of each 21-day cycle) and peginterferon alfa-2a (180 micrograms (mcg) subcutaneous \[SC\] every week during each 21-day cycle) until at least 6 cycles (18 weeks) or disease progression, intolerable toxicity, or consent withdrawal.

    Drug: Capecitabine · Drug: Peginterferon alfa-2a

Interventions

  • Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.

    Also known as: Xeloda

  • Participants will receive SC peginterferon alfa-2a, 180 mcg every week during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.

    Also known as: Pegasys

06

What researchers measure

Primary outcomes

  1. Objective response rate

    Time frame: up to post-chemotherapy follow-up ( approximately 46 months)

Secondary outcomes

  1. Time to disease progression

    Time frame: Up to approximately 46 months

  2. Duration of response

    Time frame: Up to approximately 46 months

  3. Overall survival

    Time frame: Up to approximately 46 months

  4. Incidence of adverse events

    Time frame: Up to approximately 46 months

07

Study locations

8 sites
  • Beijing, 100050, China
  • Guangzhou, 510060, China
  • Kueishan, 333, Taiwan
  • Tainan, 704, Taiwan
  • Bangkok, 10400, Thailand
  • Bangkok, 10700, Thailand
  • Chiang Mai, 50202, Thailand
  • Songkhla, 90112, Thailand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2015
First posted
Oct 15, 2015
Start
Jan 2005
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02576964
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 15, 2015
Start date
Jan 2005
Primary completion
Nov 2008
Completion
Nov 2008
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Peginterferon alfa-2a

Start the discussion